EP1093348A4 - Compositions antalgiques transdermiques et leurs methodes d'administration - Google Patents

Compositions antalgiques transdermiques et leurs methodes d'administration

Info

Publication number
EP1093348A4
EP1093348A4 EP99932017A EP99932017A EP1093348A4 EP 1093348 A4 EP1093348 A4 EP 1093348A4 EP 99932017 A EP99932017 A EP 99932017A EP 99932017 A EP99932017 A EP 99932017A EP 1093348 A4 EP1093348 A4 EP 1093348A4
Authority
EP
European Patent Office
Prior art keywords
methods
pain relief
transdermal compositions
transdermal
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99932017A
Other languages
German (de)
English (en)
Other versions
EP1093348A1 (fr
Inventor
Robert W Murdock
C Donald Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHARMACEUTICALS APPLICATIONS ASOCIATES LLC
PHARMACEUTICALS APPLIC ASOCIAT
Original Assignee
PHARMACEUTICALS APPLICATIONS ASOCIATES LLC
PHARMACEUTICALS APPLIC ASOCIAT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/106,684 external-priority patent/US6290986B1/en
Application filed by PHARMACEUTICALS APPLICATIONS ASOCIATES LLC, PHARMACEUTICALS APPLIC ASOCIAT filed Critical PHARMACEUTICALS APPLICATIONS ASOCIATES LLC
Publication of EP1093348A1 publication Critical patent/EP1093348A1/fr
Publication of EP1093348A4 publication Critical patent/EP1093348A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99932017A 1998-06-29 1999-06-29 Compositions antalgiques transdermiques et leurs methodes d'administration Withdrawn EP1093348A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/106,684 US6290986B1 (en) 1996-10-24 1998-06-29 Method and composition for transdermal administration of pharmacologic agents
US106684 1998-06-29
US12290399P 1999-03-05 1999-03-05
US122903P 1999-03-05
PCT/US1999/014653 WO2000000120A1 (fr) 1998-06-29 1999-06-29 Compositions antalgiques transdermiques et leurs methodes d'administration

Publications (2)

Publication Number Publication Date
EP1093348A1 EP1093348A1 (fr) 2001-04-25
EP1093348A4 true EP1093348A4 (fr) 2003-07-16

Family

ID=26803907

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99932017A Withdrawn EP1093348A4 (fr) 1998-06-29 1999-06-29 Compositions antalgiques transdermiques et leurs methodes d'administration

Country Status (18)

Country Link
EP (1) EP1093348A4 (fr)
JP (1) JP2002519310A (fr)
KR (1) KR20010078754A (fr)
CN (1) CN1331576A (fr)
AU (1) AU4841599A (fr)
BG (1) BG105175A (fr)
BR (1) BR9912508A (fr)
CA (1) CA2335837A1 (fr)
HR (1) HRP20000905A2 (fr)
HU (1) HUP0102728A3 (fr)
ID (1) ID28213A (fr)
IL (1) IL140420A0 (fr)
MX (1) MXPA00012767A (fr)
NO (1) NO20006604L (fr)
PL (1) PL345216A1 (fr)
SK (1) SK20012000A3 (fr)
TR (1) TR200003801T2 (fr)
WO (1) WO2000000120A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572880B2 (en) * 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
NZ500590A (en) 1997-04-22 2001-11-30 Cocensys Inc Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
EP1632235A3 (fr) * 1999-07-01 2006-06-14 Pharmacia & Upjohn Company LLC utilisation d' inhibiteurs de recaptage de noradrenaline hautement selectifs pour traiter les maladies mentales
DE60022692T2 (de) 1999-07-01 2006-06-22 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
CA2325106A1 (fr) * 1999-12-06 2001-06-06 Stanley L. Gore Compositions et methodes permettant de liberer des agents actifs dans le cerveau
IN191512B (fr) * 2000-01-21 2003-12-06 Panacea Biotech
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
EP1303265B1 (fr) * 2000-07-20 2007-07-11 Lauras AS Utilisation d'inhibiteurs de cox-2 en tant qu'immunostimulants dans le traitement du vih ou du sida
DE10042412B4 (de) * 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
JP2005154368A (ja) * 2003-11-27 2005-06-16 Teikoku Seiyaku Co Ltd ジソピラミド含有神経因性疼痛の鎮痛剤
JP4807721B2 (ja) * 2004-01-29 2011-11-02 株式会社 メドレックス 消炎鎮痛外用剤
AU2005287175B2 (en) 2004-09-17 2011-12-01 Durect Corporation Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP2007308403A (ja) * 2006-05-17 2007-11-29 Kenji Yoshida 皮膚外用剤
KR100880748B1 (ko) * 2006-08-29 2009-02-02 정헌택 디메톡시커큐민을 함유하는 혈관재협착 방지용 조성물
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
US9511016B2 (en) * 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
EP2219622A1 (fr) 2007-12-06 2010-08-25 Durect Corporation Procédés utiles dans le traitement de la douleur, d'états rhumatismaux ou d'inflammations associées à un état chronique
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
KR101237927B1 (ko) * 2009-05-07 2013-03-04 (주)문엔제이 신경손상 및 신경질환 예방 또는 치료용 약학조성물
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
AU2015217309A1 (en) * 2014-02-11 2016-08-25 Dr. Reddy's Laboratories Ltd. Parenteral compositions of celecoxib
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
AU2019365255B2 (en) 2018-10-26 2025-06-12 Viramal Limited Mucoadhesive gel composition
EP3659583B1 (fr) 2018-11-30 2023-06-07 Viramal Limited Procédé de préparation d'un agent coagulant, agent coagulant ainsi obtenu et utilisation de cet agent coagulant
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
FR3108841B1 (fr) * 2020-04-06 2023-11-03 Algotherapeutix Composition pharmaceutique topique sous forme de gel aqueux comprenant au moins de l’amitriptyline
CA3203561A1 (fr) 2021-01-12 2022-07-21 Adrian Neil Verity Systemes d'administration de medicament a liberation prolongee et procedes associes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395420A (en) * 1981-12-09 1983-07-26 Bernstein Joel E Method and composition for treating pruritis
WO1994008623A1 (fr) * 1992-10-14 1994-04-28 F. Hoffmann-La Roche Ag Gel de lecithine injectable
US5731000A (en) * 1993-07-30 1998-03-24 Glaxo Wellcome Inc. Stabilized pharmaceutical composition containing bupropion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US5885597A (en) * 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395420A (en) * 1981-12-09 1983-07-26 Bernstein Joel E Method and composition for treating pruritis
WO1994008623A1 (fr) * 1992-10-14 1994-04-28 F. Hoffmann-La Roche Ag Gel de lecithine injectable
US5731000A (en) * 1993-07-30 1998-03-24 Glaxo Wellcome Inc. Stabilized pharmaceutical composition containing bupropion

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAILEY: "percutaneous Absorption of tricyclic antidepressants", J.ANAL.TOXICOL., vol. 14, 1990, pages 217 - 218, XP009010975 *
EGBUNIKE ET AL: "Antidepressants in the management of chronic pain syndromes", PHARMACOTHERAPY, vol. 10, no. 4, 1990, pages 262 - 270, XP002241432 *
SCOTT ET AL: "Use of Transdermal Amitripyline gel in a patient with chronic pai and depression.", PHAMACOTHERAPY, vol. 19, no. 2, 1999, pages 236 - 239, XP000909357 *
See also references of WO0000120A1 *
WATSON: "Antidepressant Drugs as Adjuvant Analgesics", J.PAIN AND SYMPTOM MANAGEMENT, vol. 9, no. 6, 1994, pages 392 - 405, XP009011036 *
WILLIMANN H ET AL: "LECITHIN ORGANOGEL AS MATRIX FOR TRANSDERMAL TRANSPORT OF DRUGS", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 81, no. 19, 1 September 1992 (1992-09-01), pages 871 - 874, XP000371811, ISSN: 0022-3549 *

Also Published As

Publication number Publication date
WO2000000120A9 (fr) 2000-03-30
CA2335837A1 (fr) 2000-01-06
CN1331576A (zh) 2002-01-16
HUP0102728A3 (en) 2002-12-28
AU4841599A (en) 2000-01-17
TR200003801T2 (tr) 2001-06-21
BG105175A (bg) 2001-11-30
PL345216A1 (en) 2001-12-03
SK20012000A3 (sk) 2001-08-06
BR9912508A (pt) 2001-05-02
ID28213A (id) 2001-05-10
IL140420A0 (en) 2002-02-10
JP2002519310A (ja) 2002-07-02
WO2000000120A1 (fr) 2000-01-06
NO20006604L (no) 2001-02-28
HUP0102728A2 (hu) 2002-03-28
HRP20000905A2 (en) 2001-08-31
MXPA00012767A (es) 2002-08-09
NO20006604D0 (no) 2000-12-22
EP1093348A1 (fr) 2001-04-25
KR20010078754A (ko) 2001-08-21

Similar Documents

Publication Publication Date Title
HUP0102728A3 (en) Methods and transdermal compositions for pain relief
AU2002234192A8 (en) Methods and transdermal compositions for pain relief
AU2024500A (en) Intraoral electromuscular stimulation device and method
AU6872498A (en) Method and composition for skin treatment
HUP0103621A3 (en) Fentanyl composition for the treatment of acute pain
AU2577299A (en) Implantable therapeutic device and method
AU5439996A (en) Compositions and methods for treating pain
PL329211A1 (en) Pain relieving method
AU7696098A (en) Substance p inhibitors in combination with nmda-blockers for treating pain
AU3877900A (en) Compositions and methods for preventing and treating sexual dysfunctions
IL116895A (en) Transdermal patch comprising xanomeline
AU2542097A (en) Oligonucleotide treatments and compositions for human melanoma
AU3784999A (en) Methods for treatment of pain
AU6056500A (en) Process and composition for temporarily suppressing pain
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
PL329217A1 (en) Pain relieving method
AU3204899A (en) Hair treatment composition and method
EP1007041A4 (fr) Composition analgesique
AU2420101A (en) Method and composition for the treatment of pain
AU5169200A (en) Methods and compositions for treating breakthrough pain
AU7247898A (en) Composition for treating pain
HUP0300043A3 (en) Method and composition for the treatment of pain
AU5097099A (en) Methods and compositions for cancer treatment
AU5768300A (en) Pain relief composition and method of relieving pain
AU6106599A (en) Device for use in treatment of hair

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 29/00 B

Ipc: 7A 61K 31/44 B

Ipc: 7A 61K 9/06 B

Ipc: 7A 61F 13/02 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030602

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030819